Has Aron Bender, MD received payments from drug or device companies?

Yes. Drug and device makers reported $60,373 in general payments to Aron Bender, MD across 267 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aron Bender, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aron Bender, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aron Bender, MD

Cardiovascular Disease · Seattle, WANPI 1629412895

Payments from drug & device makers

What this record shows

This record is dominated by grants: $37,647 of the $60,373 with a category attached, or 62.4%. 12 manufacturers reported payments, led by Medtronic at 43.1% of the total. Reporting peaked in 2019 at $30,026 and has fallen 62.7% since, to $11,204 in 2025. Among cardiovascular disease clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$60,373in general payments, 2019–2025

Across 267 payments — averaging $226.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$26K
Boston Scientific$15K
Abbott$7K
Philips North America LLC$6K
Impulse Dynamics (USA) Inc.$4K
Biosense Webster, Inc.$1K
plus $816 from 6 others

What the payments were for

Consulting fees$8,37214%
Speaking & faculty fees$9402%
Grants$37,64762%
Travel & lodging$5,1889%
Food & beverage$8,22714%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	49	$26,023
Boston Scientific	66	$15,345
Abbott	68	$6,501
Philips North America LLC	32	$6,146
Impulse Dynamics (USA) Inc.	6	$4,425
Biosense Webster, Inc.	11	$1,118
Biotronik Inc.	17	$472
Cardiva Medical, Inc.	14	$247
Altathera Pharmaceuticals LLC	1	$47
Angiodynamics, Inc.	1	$18
Chiesi USA, Inc.	1	$16
Novartis	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL BRADY$12,500
(9520) IGT Devices Undivided$3,925
AVEIR$2,041
(9124) LM Undivided$1,184
Confirm Rx$1,088
TENDRIL$975
EMBLEM MRI S-ICD$857
GALLANT$675
ENSITE$327
IGT Devices Und$287
Carto 3$258
TACTICATH ABLATION CATHETER, SENSOR ENABLED$179
LUX-Dx Insertable Cardiac Monitor$138
GENERAL - THERAPIES$133
S ICD$121

How this compares

$60,373 in reported general payments places this provider in the 95th percentile of 370 cardiovascular disease providers in Washington.

See all cardiovascular disease providers in Washington →

Medicare billing

Part B allowed, 2024

$227,852

Medicare patients

958

Services billed

2,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	207	$283,249
XareltoRivaroxaban	55	$82,138
MultaqDronedarone Hcl	33	$52,962
Propafenone Hcl ErPropafenone Hcl	13	$2,737
Flecainide Acetate	73	$2,665
Metoprolol Succinate	143	$2,533
Amiodarone Hcl	105	$1,939
Verapamil ErVerapamil Hcl	26	$673
Diltiazem 24hr Er (Cd)Diltiazem Hcl	15	$234
Metoprolol Tartrate	19	$218
Amlodipine Besylate	30	$182
Carvedilol	25	$103
Propranolol Hcl	11	$15

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Seattle

Mariko HarperSeattle$246K
Gary OppenheimSeattle$153K
Kelley BranchSeattle$103K
Erik WissnerSeattle$67K
Younghoon KwonSeattle$66K
Vidhushei YogeswaranSeattle$55K
Santanu BiswasSeattle$30K
Bhanu GuptaSeattle$27K
Michael LongoSeattle$22K
Oana PetrescuSeattle$13K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →